<DOC>
	<DOCNO>NCT01234311</DOCNO>
	<brief_summary>This Phase 3 randomize , double blind , placebo control study tasquinimod asymptomatic mildly symptomatic patient metastatic CRPC confirm effect tasquinimod delay disease progression compare placebo . Approximately 1200 eligible patient metastatic CRPC randomly assign 2:1 ratio 1 2 treatment group : Treatment Group A ( tasquinimod 0.25 , 0.5 , 1 mg/day ; n=800 ) Treatment Group B ( placebo ; n=400 ) .</brief_summary>
	<brief_title>A Study Tasquinimod Men With Metastatic Castrate Resistant Prostate Cancer</brief_title>
	<detailed_description>This Phase 3 randomize , double blind , placebo control study tasquinimod asymptomatic mildly symptomatic patient metastatic CRPC confirm effect tasquinimod delay disease progression compare placebo . Approximately 1200 eligible patient metastatic CRPC randomly assign 2:1 ratio 1 2 treatment group : Treatment Group A ( tasquinimod 0.25 , 0.5 , 1 mg/day ; n=800 ) Treatment Group B ( placebo ; n=400 ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Age least 18 year time signing informed consent form . For patient Taiwan minimum age 20 year . 2 . Histologically confirm diagnosis adenocarcinoma prostate . 3 . Evidence bone metastatic disease radiographic examination , whether bone scan imaging modality . 4 . Castrate level serum testosterone ( ≤50 ng/dL 1.7 nmol/L ) . 5 . Evidence progressive disease . 6 . Karnofsky score ≥70 % . 7 . Meet screen laboratory value specify thr protocol . 8 . If sexually active partner childbearing potential , patient agree use adequate contraceptive method ( barrier contraceptive spermicide vasectomy ) study drug . The adequate contraceptive method continue 14 day patient stop take study drug . 9 . No evidence ( within 5 year ) prior malignancy ( except successfully treat basal cell squamous cell carcinoma skin ) . 10 . Able swallow retain oral medication . 11 . Able adhere study visit schedule protocol requirement . 12 . Ability comprehend full nature purpose study , include possible risk side effect ; ability cooperate investigator comply requirement entire study . 13 . Able ( patient 's legal guardian , applicable ) sign date write informed consent inform full nature purpose study , include possible risk side effect , give ample time opportunity read understand information . 1 . Prior cytotoxic chemotherapy treatment prostate ca within 2 year within 4 week Estracyt ( estramustine ) prior study treatment . 2 . Previous anticancer therapy use radiation , biologics vaccine , include abiraterone , TAK700 ( Orteronel ) , MDV3100 within 4 week prior sipuleucelT ( Provenge ) within 2 week prior start study treatment . If radiation therapy apply baseline scan , new baseline scan need do least 4 week radiation therapy . 3 . Previous therapy antiandrogens within 4 week ( within 6 week bicalutamide eg , Casodex® ) prior study treatment . 4 . Concurrent use anticancer agent treatment , follow exception : • Ongoing treatment luteinizing hormonereleasing hormone agonist antagonist , denosumab ( Prolia ) bisphosphonate ( eg , zoledronic acid ) allow . Ongoing treatment keep stable schedule ; however , medically require , change dose , compound , allow . 5 . Any treatment modality involve major surgery within 4 week prior start study treatment . 6 . Prostate ca pain require ongoing treatment narcotic analgesic warrant initiation radio chemotherapy . 7 . Ongoing treatment warfarin unless international normalize ratio ( INR ) well control 4 ( Section 4.6.8.1 ) . 8 . Maintenance treatment corticosteroid correspond prednisolone prednisone dose 10 mg/day . The dose must stable least 5 day . 9 . Systemic exposure ketoconazole strong cytochrome P450 ( CYP ) 3A4 isozyme inhibitor inducer within 14 day prior start study treatment . Systemic exposure amiodarone allow within 1 year prior start study treatment . 10 . Ongoing treatment sensitive CYP1A2 substrate CYP1A2 substrate narrow therapeutic range start study treatment . 11 . Ongoing treatment CYP3A4 substrate narrow therapeutic range start study treatment . 12 . Simultaneous participation study involve treatment investigational drug receive treatment investigational drug le 4 week prior start study treatment . 13 . Myocardial infarction , percutaneous coronary intervention , acute coronary syndrome , coronary artery bypass graft , class III/IV congestive heart failure , cerebrovascular accident , transient ischemic attack , limb claudication rest , within 6 month prior start study treatment ongoing symptomatic dysrhythmias , unstable angina , uncontrolled hypertension , uncontrolled atrial ventricular arrhythmia . 14 . History pancreatitis . 15 . Known brain epidural metastasis . 16 . Known positive serology HIV ( patient know history HIV exclude potential unforeseen toxicity morbidity immunocompromised host ) . 17 . Chronic hepatitis advance , decompensated hepatic disease cirrhosis liver history chronic viral hepatitis know viral hepatitis carrier ( patient recover hepatitis allow enter study ) . 18 . Patients active tuberculosis ( TB ) , know , untreated latent TB . ( Countryspecific TB therapy give least 30 day prior start study treatment patient intend complete entire course therapy . ) 19 . Any condition , include active latent infection , medical psychiatric condition , presence laboratory abnormality , could confound ability interpret data study place patient unacceptable risk participates study . 20 . Any patient opinion investigator participate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>